A clinical trial titled "Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)" was listed with a status update on October 22, 2026. The trial, registered under identifier NCT07890012, currently has a status of not yet recruiting. No phase has been specified for this study in the available record.
The trial focuses on how tyrosine kinase inhibitors are positioned within broader systemic treatment strategies for patients with advanced neuroendocrine tumors, according to the listing. As the study has not yet begun recruiting participants, no enrollment, results, or outcome data are currently available.
Somatostatin, which is associated with neuroendocrine tumor research, remains classified as an unapproved research compound. This trial update does not provide information on somatostatin's role, efficacy, or safety within this study or any other context. No results or interim findings have been reported as part of this update.
Readers interested in learning more about neuroendocrine tumor treatment research can refer to the official trial registration for further status updates as they become available. For general background on somatostatin, see the compound overview.